Supplementary Table S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Year: 2026
Type: supplementary-materials
Abstract: Table S1 shows the Olink IO panel analytes.
Authors: Ziao Li, Sudeh Izadmehr, Jeannie Hoffman-Censits, Benjamin Maughan, Tina Mayer, Alan Tan, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Giorgio Ioannou, Rafael Cabal, Kevin Tuballes, Ruiwei Guo, Igor Figueiredo, Diane M. Del Valle, Reza Mehrazin, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, John P. Sfakianos, Santosh Gupta, Noah M. Hahn, Edgar Gonzalez-Kozlova, Sacha Gnjatic, Matthew D. Galsky
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7169625545
Cites:
Cited by:
Related to: